Combination of a Proteomics Approach and Reengineering of Meso Scale Network Models for Prediction of Mode-of-Action for Tyrosine Kinase Inhibitors

PLoS ONE

Volumn 8, Issue 1, 2013, Pages

  Balabanov, Stefan ^a,b   Wilhelm, Thomas ^a,c   Venz, Simone ^d   Keller, Gunhild ^a   Scharf, Christian ^d   Pospisil, Heike ^e   Braig, Melanie ^a   Barett, Christine ^a   Bokemeyer, Carsten ^a   Walther, Reinhard ^d   Brümmendorf, Tim H ^a,c   Schuppert, Andreas ^c  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^c RWTH AACHEN UNIVERSITY   (Germany)

^d UNIVERSITY OF GREIFSWALD   (Germany)

^e TECHNICAL UNIVERSITY OF APPLIED SCIENCES WILDAU   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BCR ABL PROTEIN; DANUSERTIB; DASATINIB; IMATINIB; NILOTINIB; PROTEIN TYROSINE KINASE INHIBITOR;

ANIMAL CELL; APOPTOSIS; ARTICLE; BIOENGINEERING; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; DRUG PROTEIN BINDING; DRUG SELECTIVITY; ENZYME INHIBITION; GENE MUTATION; GENETIC MODEL; LEUKEMIA CELL LINE; MASS SPECTROMETRY; MESO SCALE NETWORK REENGINEERING; MOLECULARLY TARGETED THERAPY; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PREDICTION; PROTEIN ANALYSIS; PROTEIN DETERMINATION; PROTEIN ENGINEERING; PROTEIN EXPRESSION; PROTEIN INDUCTION; PROTEIN PHOSPHORYLATION; PROTEIN PROCESSING; PROTEOMICS; TWO DIMENSIONAL GEL ELECTROPHORESIS; WILD TYPE;

ANIMALS; APOPTOSIS; BENZAMIDES; BLOTTING, WESTERN; CELL LINE, TUMOR; CLUSTER ANALYSIS; DRUG RESISTANCE, NEOPLASM; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MICE; MODELS, BIOLOGICAL; NEOPLASM PROTEINS; PIPERAZINES; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; PROTEOMICS; PYRIMIDINES; SIGNAL TRANSDUCTION;

EID: 84872252444     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0053668     Document Type: Article

References (63)

1. Sebolt-Leopold JS, English JM, (2006) Mechanisms of drug inhibition of signalling molecules. Nature 441: 457-462.
2. Cohen P, (2002) Protein kinases [mdash] the major drug targets of the twenty-first century? Nat Rev Drug Discov 1: 309-315.
3. Dancey J, Sausville EA, (2003) Issues and progress with protein kinase inhibitors for cancer treatment. Nat Rev Drug Discov 2: 296-313.
4. Bain J, McLauchlan H, Elliott M, Cohen P, (2003) The specificities of protein kinase inhibitors: an update. The Biochemical journal 371: 199-204.
5. Karaman MW, Herrgard S, Treiber DK, Gallant P, Atteridge CE, et al. (2008) A quantitative analysis of kinase inhibitor selectivity. Nat Biotech 26: 127-132.
6. Ross-Macdonald P, de Silva H, Guo Q, Xiao H, Hung C-Y, et al. (2008) Identification of a nonkinase target mediating cytotoxicity of novel kinase inhibitors. Molecular Cancer Therapeutics 7: 3490-3498.
7. Fabian MA, Biggs WH, Treiber DK, Atteridge CE, Azimioara MD, et al. (2005) A small molecule-kinase interaction map for clinical kinase inhibitors. Nat Biotech 23: 329-336.
8. Bhojani N, Jeldres C, Patard JJ, Perrotte P, Suardi N, et al. (2008) Toxicities associated with the administration of sorafenib, sunitinib, and temsirolimus and their management in patients with metastatic renal cell carcinoma. European urology 53: 917-930.
9. Quintas-Cardama A, Cortes JE, Kantarjian H, (2008) Practical management of toxicities associated with tyrosine kinase inhibitors in chronic myeloid leukemia. Clinical lymphoma & myeloma 8Suppl 3: S82-88.
10. Force T, Kolaja KL, (2011) Cardiotoxicity of kinase inhibitors: the prediction and translation of preclinical models to clinical outcomes. Nat Rev Drug Discov 10: 111-126.
11. Al-Lazikani B, Banerji U, Workman P, (2012) Combinatorial drug therapy for cancer in the post-genomic era. Nat Biotechnol 30: 679-692.
12. Pauwels E, Stoven V, Yamanishi Y, (2011) Predicting drug side-effect profiles: a chemical fragment-based approach. BMC Bioinformatics 12: 169.
13. Atias N, Sharan R, (2011) An algorithmic framework for predicting side effects of drugs. J Comput Biol 18: 207-218.
14. Jin G, Fu C, Zhao H, Cui K, Chang J, et al. (2012) A novel method of transcriptional response analysis to facilitate drug repositioning for cancer therapy. Cancer research 72: 33-44.
15. McArt DG, Zhang SD, (2011) Identification of candidate small-molecule therapeutics to cancer by gene-signature perturbation in connectivity mapping. PloS one 6: e16382.
16. Sirota M, Dudley JT, Kim J, Chiang AP, Morgan AA, et al. (2011) Discovery and preclinical validation of drug indications using compendia of public gene expression data. Science translational medicine 3: 96ra77.
17. Fukuzaki M, Seki M, Kashima H, Sese J (2009) Side Effect Prediction Using Cooperative Pathways. Proceedings of the 2009 IEEE International Conference on Bioinformatics and Biomedicine: IEEE Computer Society. 142-147.
18. Lehar J, Zimmermann GR, Krueger AS, Molnar RA, Ledell JT, et al. (2007) Chemical combination effects predict connectivity in biological systems. Mol Syst Biol 3: 80.
19. Peifer M, Weiss J, Sos ML, Koker M, Heynck S, et al. (2010) Analysis of compound synergy in high-throughput cellular screens by population-based lifetime modeling. PloS one 5: e8919.
20. Fitzgerald JB, Schoeberl B, Nielsen UB, Sorger PK, (2006) Systems biology and combination therapy in the quest for clinical efficacy. Nat Chem Biol 2: 458-466.
21. Zhao XM, Iskar M, Zeller G, Kuhn M, van Noort V, et al. (2011) Prediction of drug combinations by integrating molecular and pharmacological data. PLoS Comput Biol 7: e1002323.
22. Gardner TS, di Bernardo D, Lorenz D, Collins JJ, (2003) Inferring Genetic Networks and Identifying Compound Mode of Action via Expression Profiling. Science 301: 102-105.
23. Xing H, Gardner TS, (2006) The mode-of-action by network identification (MNI) algorithm: a network biology approach for molecular target identification. Nature protocols 1: 2551-2554.
24. di Bernardo D, Thompson MJ, Gardner TS, Chobot SE, Eastwood EL, et al. (2005) Chemogenomic profiling on a genome-wide scale using reverse-engineered gene networks. Nature biotechnology 23: 377-383.
25. Kutalik Z, Beckmann JS, Bergmann S, (2008) A modular approach for integrative analysis of large-scale gene-expression and drug-response data. Nature biotechnology 26: 531-539.
26. Mitsos A, Melas IN, Siminelakis P, Chairakaki AD, Saez-Rodriguez J, et al. (2009) Identifying drug effects via pathway alterations using an integer linear programming optimization formulation on phosphoproteomic data. PLoS computational biology 5: e1000591.
27. Schuppert A, (2011) Efficient reengineering of meso-scale topologies for functional networks in biomedical applications. Journal of Mathematics in Industry 1: 6.
28. Fiedler B, Schuppert A, (2008) Local identification of scalar hybrid models with tree structure. IMA Journal of Applied Mathematics 73: 449-476.
29. Schopfer G, Kahrs O, Marquardt W, Warncke M, Mrziglod T, et al. (2005) Semi-empirical process modelling with integration of commercial modelling tools; Espuña LPaA, editor. Barcelona, Spain. 595-600 p.
30. Schuppert A (1999) Extrapolability of structured hybrid models: A key to the optimization of complex processes.; Fiedler B, Groeger K, Sprekels J, editors. Singapore: World Scientific Publishing.
31. Ren R, (2005) Mechanisms of BCR-ABL in the pathogenesis of chronic myelogenous leukaemia. Nature reviews Cancer 5: 172-183.
32. Druker BJ, Guilhot F, O'Brien SG, Gathmann I, Kantarjian H, et al. (2006) Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. The New England journal of medicine 355: 2408-2417.
33. Saglio G, Kim DW, Issaragrisil S, le Coutre P, Etienne G, et al. (2010) Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. The New England journal of medicine 362: 2251-2259.
34. Kantarjian H, Shah NP, Hochhaus A, Cortes J, Shah S, et al. (2010) Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. The New England journal of medicine 362: 2260-2270.
35. Cortes JE, Kantarjian HM, Brummendorf TH, Kim DW, Turkina AG, et al. (2011) Safety and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia chromosome-positive CML patients with resistance or intolerance to imatinib. Blood.
36. Keller G, Schafhausen P, Brummendorf TH, (2009) Bosutinib: a dual SRC/ABL kinase inhibitor for the treatment of chronic myeloid leukemia. Expert review of hematology 2: 489-497.
37. Cortes JE, Kim D-W, Kantarjian HM, Brümmendorf TH, Dyagil I, et al. (2012) Bosutinib Versus Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia: Results From the BELA Trial. Journal of Clinical Oncology.
38. Gontarewicz A, Balabanov S, Keller G, Colombo R, Graziano A, et al. (2008) Simultaneous targeting of Aurora kinases and Bcr-Abl kinase by the small molecule inhibitor PHA-739358 is effective against imatinib-resistant BCR-ABL mutations including T315I. Blood 111: 4355-4364.
39. Wei G, Rafiyath S, Liu D, (2010) First-line treatment for chronic myeloid leukemia: dasatinib, nilotinib, or imatinib. Journal of hematology & oncology 3: 47.
40. O'Hare T, Deininger MW, Eide CA, Clackson T, Druker BJ, (2011) Targeting the BCR-ABL signaling pathway in therapy-resistant Philadelphia chromosome-positive leukemia. Clinical cancer research: an official journal of the American Association for Cancer Research 17: 212-221.
41. O'Hare T, Shakespeare WC, Zhu X, Eide CA, Rivera VM, et al. (2009) AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance. Cancer cell 16: 401-412.
42. Modugno M, Casale E, Soncini C, Rosettani P, Colombo R, et al. (2007) Crystal structure of the T315I Abl mutant in complex with the aurora kinases inhibitor PHA-739358. Cancer research 67: 7987-7990.
43. Winkler DA, Burden FR, Halley JD, (2009) Predictive mesoscale network model of cell fate decisions during C. elegans embryogenesis. Artificial life 15: 411-421.
44. Laubenbacher R, Stigler B, (2004) A computational algebra approach to the reverse engineering of gene regulatory networks. Journal of theoretical biology 229: 523-537.
45. Hughes TR, Marton MJ, Jones AR, Roberts CJ, Stoughton R, et al. (2000) Functional discovery via a compendium of expression profiles. Cell 102: 109-126.
46. Lamb J, Crawford ED, Peck D, Modell JW, Blat IC, et al. (2006) The Connectivity Map: using gene-expression signatures to connect small molecules, genes, and disease. Science 313: 1929-1935.
47. Nilsson T, Mann M, Aebersold R, Yates JR, 3rd, Bairoch A, et al (2010) Mass spectrometry in high-throughput proteomics: ready for the big time. Nature methods 7: 681-685.
48. Bantscheff M, Eberhard D, Abraham Y, Bastuck S, Boesche M, et al. (2007) Quantitative chemical proteomics reveals mechanisms of action of clinical ABL kinase inhibitors. Nature biotechnology 25: 1035-1044.
49. Rix U, Hantschel O, Durnberger G, Remsing Rix LL, Planyavsky M, et al. (2007) Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib reveal novel kinase and nonkinase targets. Blood 110: 4055-4063.
50. Breitkopf SB, Oppermann FS, Keri G, Grammel M, Daub H, (2010) Proteomics analysis of cellular imatinib targets and their candidate downstream effectors. Journal of proteome research 9: 6033-6043.
51. Brehme M, Hantschel O, Colinge J, Kaupe I, Planyavsky M, et al. (2009) Charting the molecular network of the drug target Bcr-Abl. Proceedings of the National Academy of Sciences of the United States of America 106: 7414-7419.
52. Balabanov S, Gontarewicz A, Ziegler P, Hartmann U, Kammer W, et al. (2007) Hypusination of eukaryotic initiation factor 5A (eIF5A): a novel therapeutic target in BCR-ABL-positive leukemias identified by a proteomics approach. Blood 109: 1701-1711.
53. Preisinger C, Kolch W, (2010) The Bcr-Abl kinase regulates the actin cytoskeleton via a GADS/Slp-76/Nck1 adaptor protein pathway. Cell Signal 22: 848-856.
54. Guo F, Sigua C, Bali P, George P, Fiskus W, et al. (2005) Mechanistic role of heat shock protein 70 in Bcr-Abl-mediated resistance to apoptosis in human acute leukemia cells. Blood 105: 1246-1255.
55. Shiotsu Y, Neckers LM, Wortman I, An WG, Schulte TW, et al. (2000) Novel oxime derivatives of radicicol induce erythroid differentiation associated with preferential G(1) phase accumulation against chronic myelogenous leukemia cells through destabilization of Bcr-Abl with Hsp90 complex. Blood 96: 2284-2291.
56. Park D, Choi SS, Ha KS, (2010) Transglutaminase 2: a multi-functional protein in multiple subcellular compartments. Amino Acids 39: 619-631.
57. Khoury HJ, Cortes JE, Kantarjian HM, Gambacorti-Passerini C, Baccarani M, et al. (2012) Bosutinib is active in chronic phase chronic myeloid leukemia after imatinib and dasatinib and/or nilotinib therapy failure. Blood 119: 3403-3412.
58. Gorre ME, Mohammed M, Ellwood K, Hsu N, Paquette R, et al. (2001) Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 293: 876-880.
59. Shah NP, Nicoll JM, Nagar B, Gorre ME, Paquette RL, et al. (2002) Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell 2: 117-125.
60. Ummanni R, Mundt F, Pospisil H, Venz S, Scharf C, et al. (2011) Identification of clinically relevant protein targets in prostate cancer with 2D-DIGE coupled mass spectrometry and systems biology network platform. PloS one 6: e16833.
61. Ummanni R, Barreto F, Venz S, Scharf C, Barett C, et al. (2012) Peroxiredoxins 3 and 4 are overexpressed in prostate cancer tissue and affect the proliferation of prostate cancer cells in vitro. Journal of proteome research 11: 2452-2466.
62. Dyshlovoy SA, Naeth I, Venz S, Preukschas M, Sievert H, et al. (2012) Proteomic profiling of germ cell cancer cells treated with aaptamine, a marine alkaloid with antiproliferative activity. J Proteome Res 11: 2316-2330.
63. Preukschas M, Hagel C, Schulte A, Weber K, Lamszus K, et al. (2012) Expression of Eukaryotic Initiation Factor 5A and Hypusine Forming Enzymes in Glioblastoma Patient Samples: Implications for New Targeted Therapies. PloS one 7: e43468.